Published in J Virol on August 01, 2003
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol (2006) 1.10
More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis (2006) 1.03
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
Plant-based vaccines against viruses. Virol J (2014) 0.95
Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol (2011) 0.91
Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90
Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol J (2009) 0.88
Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines (2013) 0.88
Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine (2009) 0.86
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
Human papillomavirus genotyping and integration in ovarian cancer Saudi patients. Virol J (2013) 0.83
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLoS One (2015) 0.81
Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine (2014) 0.79
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. J Virol (2016) 0.78
The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy. J Virol (2015) 0.78
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Vaccine (2015) 0.77
Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res (2016) 0.76
Characterization of an RNA aptamer against HPV-16 L1 virus-like particles. Nucleic Acid Ther (2014) 0.75
From plant virology to vaccinology: The road less travelled. Hum Vaccin Immunother (2015) 0.75
Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines (2016) 0.75
Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells. Sci Rep (2016) 0.75
Human papillomavirus type 16 DNA sequence. Virology (1985) 9.44
Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta (1996) 7.79
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Atomic model of the papillomavirus capsid. EMBO J (2002) 2.27
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J Virol (1998) 1.85
Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol (1997) 1.66
Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol (1999) 1.66
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A (1998) 1.59
Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol (2001) 1.55
Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine (1995) 1.53
Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J Virol (1998) 1.52
Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52
Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology (2001) 1.52
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol (2001) 1.46
Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol (2001) 1.44
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology (1998) 1.38
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology (2001) 1.34
An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. J Virol (1990) 1.27
Chimeric papillomavirus-like particles. Virology (1997) 1.17
Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine (2001) 1.15
HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 1.11
Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology (2002) 1.08
Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol (2001) 1.05
Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology (2001) 1.00
Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine (2001) 0.99
Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer (1999) 0.97
Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther (2001) 0.96
Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Intervirology (1996) 0.93
Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol (2001) 0.92
Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res (2000) 0.90
Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem (1999) 0.88
Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol (2002) 0.86
Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology (2000) 0.85
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One (2013) 1.83
Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem (2007) 1.77
Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology (2005) 1.73
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol (2006) 1.67
Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol (2008) 1.62
HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer (2006) 1.54
Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control (2009) 1.52
Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. J Infect Dis (2009) 1.50
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48
Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns. Reprod Sci (2007) 1.43
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology (2004) 1.37
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol (2008) 1.35
Propagation, infection, and neutralization of authentic HPV16 virus. Virology (2004) 1.32
Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J Virol (2008) 1.31
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
The evolutionary value of recombination is constrained by genome modularity. PLoS Genet (2005) 1.26
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study. BMC Cancer (2009) 1.23
Quantitative RT-PCR assay for HPV infection in cultured cells. J Virol Methods (2003) 1.23
A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis (2004) 1.23
Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol (2005) 1.22
Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology (2009) 1.21
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol (2009) 1.20
The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo. J Virol (2004) 1.18
Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol (2009) 1.18
A proposal to change existing virus species names to non-Latinized binomials. Arch Virol (2010) 1.18
Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology (2004) 1.16
Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J Virol (2002) 1.15
Agreement between self- and clinician-collected specimen results for detection and typing of high-risk human papillomavirus in specimens from women in Gugulethu, South Africa. J Clin Microbiol (2007) 1.12
High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia. J Med Virol (2003) 1.12
Recombination, decreased host specificity and increased mobility may have driven the emergence of maize streak virus as an agricultural pathogen. J Gen Virol (2008) 1.12
Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection. J Virol Methods (2007) 1.11
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine (2006) 1.10
Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol (2006) 1.10
Impact of genetic changes to the CRPV genome and their application to the study of pathogenesis in vivo. Virology (2006) 1.10
An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol (2006) 1.09
Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol (2006) 1.08
Next-generation sequencing of cervical DNA detects human papillomavirus types not detected by commercial kits. Virol J (2012) 1.08
Papillomavirus particles assembled in 293TT cells are infectious in vivo. J Virol (2006) 1.08
Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control (2003) 1.08
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology (2007) 1.07
Two methods of self-sampling compared to clinician sampling to detect reproductive tract infections in Gugulethu, South Africa. Sex Transm Dis (2006) 1.07
The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res (2006) 1.07
Evidence of unique genotypes of beak and feather disease virus in southern Africa. J Virol (2004) 1.06
Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology (2005) 1.06
Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis (2011) 1.06
A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol (2010) 1.06
Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch Virol (2009) 1.05
Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J Clin Microbiol (2007) 1.05
Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas. J Virol (2002) 1.05
A protocol for the rapid isolation of full geminivirus genomes from dried plant tissue. J Virol Methods (2008) 1.05
Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses (2008) 1.05
More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis (2006) 1.03
The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer (2007) 1.03
Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol (2008) 1.02
Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine (2005) 1.02
Evidence of ancient papillomavirus recombination. J Gen Virol (2006) 1.01
Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines. Virology (2009) 1.01
The use of nested polymerase chain reaction and restriction fragment length polymorphism for the detection and typing of mucosal human papillomaviruses in samples containing low copy numbers of viral DNA. J Virol Methods (2002) 1.01
Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol (2008) 1.01
High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J (2009) 1.00
Rapid host adaptation by extensive recombination. J Gen Virol (2009) 1.00
A three-nucleotide mutation altering the Maize streak virus Rep pRBR-interaction motif reduces symptom severity in maize and partially reverts at high frequency without restoring pRBR-Rep binding. J Gen Virol (2005) 0.99
Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J Virol (2005) 0.99
Influence of human immunodeficiency virus and CD4 count on the prevalence of human papillomavirus in heterosexual couples. J Gen Virol (2010) 0.99
Genetic analysis of maize streak virus isolates from Uganda reveals widespread distribution of a recombinant variant. J Gen Virol (2007) 0.98
The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir Ther (2011) 0.98
Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology (2006) 0.98
Large cutaneous rabbit papillomas that persist during cyclosporin A treatment can regress spontaneously after cessation of immunosuppression. J Gen Virol (2005) 0.98
Detection of human papillomavirus in urine and cervical swabs from patients with invasive cervical cancer. J Med Virol (2003) 0.98
Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins. Vaccine (2004) 0.98
Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol (2007) 0.98
In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance. Cancer Res (2011) 0.98
Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res (2006) 0.97
Experimental evidence indicating that mastreviruses probably did not co-diverge with their hosts. Virol J (2009) 0.97
Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 DNA and virus. J Virol (2013) 0.96
A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus-like particles. Plant Biotechnol J (2013) 0.96
High-risk human papillomavirus is associated with HIV acquisition among South African female sex workers. Infect Dis Obstet Gynecol (2011) 0.96
Experimental observations of rapid Maize streak virus evolution reveal a strand-specific nucleotide substitution bias. Virol J (2008) 0.96
Impact of human immunodeficiency virus on the natural history of human papillomavirus genital infection in South African men and women. J Infect Dis (2012) 0.95
Differences in N-linked glycosylation between human surfactant protein-B variants of the C or T allele at the single-nucleotide polymorphism at position 1580: implications for disease. Biochem J (2003) 0.95
Restoration of native folding of single-stranded DNA sequences through reverse mutations: an indication of a new epigenetic mechanism. Arch Biochem Biophys (2006) 0.95
Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology. J Gen Virol (2005) 0.94
Determinants of sexual activity and its relation to cervical cancer risk among South African women. BMC Public Health (2007) 0.94
Human papillomavirus vaccines in plants. Expert Rev Vaccines (2010) 0.93
Reconstructing the history of maize streak virus strain a dispersal to reveal diversification hot spots and its origin in southern Africa. J Virol (2011) 0.93